Videos
A 64-Year-Old Male with Untreated Stage IV EGFR-Mutated NSCLC
Tania Jain, MBBS, discusses the role of ruxolitinib as treatment of graft-versus-host disease.
Aaron Gerds, MD discusses the results of a phase II BELIEVE study of luspatercept as treatment of patients with myelofibrosis-associated anemia.
William K. Oh, MD, discusses phase III studies in the prostate cancer setting which led to the use of these new treatments, such as androgen receptor targeted therapies with chemotherapy in earlier disease settings.
Stephen Boorjian, MD, discusses the efficacy results of the phase II study intravesical nadofaragene firadenovec in patients with high-grade, Bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer, which he presented at the 2020 Genitourinary Cancer Symposium.
Zofia Piotrowska, MD, MHS, discusses the data from the randomized phase III FLAURA trial, which led to the widespread use of frontline osimertinib for the treatment of EGFR-mutant lung cancers.
Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, senior physician, instructor in medicine, Harvard Medical School, discusses the goals of the phase III CheckMate-9ER trial, which is evaluating cabozantinib combined with nivolumab in previously untreated patients with advanced or metastatic renal cell carcinoma (RCC).
Alexandra Drakaki, MD, assistant professor of medicine, hematology, and oncology, University of California, Los Angeles, discusses the goals of the phase Ib/II MORPHEUS trial, which is an umbrella study evaluating several second-line immunotherapy combinations in patients with advanced or metastatic urothelial carcinoma.
Jeff P. Sharman, MD, discusses what differentiates acalabrutinib from other BTK inhibitors available in chronic lymphocytic leukemia.
Monika Joshi, MD, MRCP, associate professor of medicine, Division of Hematology-Oncology, and co-leader for Genitourinary Disease Team, at Penn State Hershey Cancer Institute, discusses the phase Ib/II results of a trial looking at concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with locally advanced urothelial cancer of the bladder.
Andrew Kuykendall, MD, discusses the current treatment landscape for the patients with myelofibrosis and how this evolved over the last decade.
Andrew J. Cowan, MD, explains the rationale for a phase I clinical trial in which a gamma-secretase inhibitor was combined with CAR T-cell therapy as treatment for heavily pretreated patients with multiple myeloma.
Karl M. Kilgore, PhD, discusses the role of chimeric antigen receptor T-cell therapy as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma and where this option might fit into the landscape in the future.
Matthew Krebs, MBChB, PhD, explains the rationale for a phase II study of bemcentinib, a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced non–small cell lung cancer, which he presented at the 2019 Society for Immunotherapy of Cancer Annual Meeting.
A 56-Year-Old Female With Recurrent Ovarian Cancer
Jason Luke, MD, FACP, discusses promising clinical research around intratumoral immunotherapy.
TKI in Poor-Risk Advanced Renal Cell Carcinoma